Congenital adrenal hyperplasia (CAH) is a genetic condition affecting hormone production. Individuals with CAH often lack sufficient cortisol and aldosterone, leading to hormonal imbalances. Traditional treatment relies on glucocorticoids—steroids—to replace missing cortisol. However, long-term steroid use carries significant risks, including weight gain, high blood pressure, and bone density loss. The search for better solutions is now yielding promising results.
The Challenges of Current CAH Treatment
Managing CAH with steroids is often a delicate balance. Precise timing and dosage are crucial, yet difficult to achieve consistently. This leads many patients to seek alternatives that could reduce steroid dependency or improve treatment accuracy.
Fortunately, research is advancing on multiple fronts, from new medications to experimental gene-editing techniques. Some approaches aim to minimize steroid dosage, while others attempt to fix the underlying genetic defect altogether.
Emerging Medications: Reducing Steroid Dependence
The U.S. Food and Drug Administration (FDA) recently approved crinecerfont (Crenessity) in 2024, a drug designed to supplement glucocorticoid treatment in patients age four and older. Crinecerfont works by reducing the production of adrenocorticotropic hormone (ACTH), lessening the body’s demand for cortisol replacement. Studies show it can lower glucocorticoid needs by up to 27 percent, though gradual dose reduction is vital to avoid withdrawal symptoms.
Another promising medication, atumelnant, is currently in Phase 3 clinical trials and has received orphan drug designation from the FDA. Unlike crinecerfont, atumelnant blocks ACTH after it’s produced. If trials proceed successfully, it could be available by 2027. Experts like Dr. Richard Auchus describe it as “very promising.”
Improving Steroid Delivery for Better Control
Traditional oral steroids don’t always align with the body’s natural cortisol fluctuations. The goal is to deliver steroids more consistently, mimicking the body’s natural rhythm. Several new approaches are being explored:
- Modified-Release Steroids: Drugs like Efmody and Plenadren, available in Europe, release hydrocortisone slowly, providing a more gradual rise and fall in cortisol levels. Despite their benefits, neither is currently approved for use in the U.S.
- Steroid Pump Therapy: Continuous subcutaneous hydrocortisone infusion (CSHI) uses a pump to deliver liquid hydrocortisone under the skin. This method closely mimics natural cortisol release, potentially reducing total steroid dosage and improving symptoms. However, pump failure can lead to life-threatening adrenal crises, requiring careful monitoring.
The Long-Term Vision: Gene Therapy for a Cure
The most ambitious approach involves repairing the defective gene responsible for CAH. Gene therapy could theoretically allow patients to produce their own hormones without medication, effectively curing the condition.
While still in early stages, research in animal models is progressing. Dr. Lara Graves notes that current therapies are “not good enough yet,” but the field is evolving rapidly. Human trials will be necessary before any gene therapy becomes a viable treatment option, but the potential is transformative.
The Bottom Line
New treatments for CAH offer a path toward improved management and reduced reliance on steroids. From approved medications like crinecerfont to experimental therapies like gene editing, the future of CAH care is evolving. Patients should discuss these options with their doctors to determine the best course of treatment. Wearable cortisol sensors and hormone-sampling kits may also help personalize treatment plans in the coming years.
